Associations between estrogen receptor-beta polymorphisms and endometriosis risk: a meta-analysis

Renyong Guo1†, Nengneng Zheng2†, Shiping Ding3, Ying Zheng2 and Limin Feng1*

Abstract

Background: Many epidemiological studies have suggested an association between estrogen receptor-beta (ER-β) polymorphisms with endometriosis risk. However, the results of these studies have been inconsistent. In the present study, we performed a meta-analysis to clarify the associations between the ER-β rs4986938 and rs1256049 polymorphisms and endometriosis risk.

Methods: Eligible publications were retrieved from the PubMed, ISI Web of Science, and several Chinese language databases. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random or fixed effect model.

Results: A total of eight studies (1100 cases/1485 controls) for the rs4986938 polymorphism and four studies (353 cases/450 controls) for the rs1256049 polymorphism were included in this meta-analysis. Regarding the rs4986938 polymorphism, no obvious associations were found for all genetic models when all studies were pooled into the meta-analysis. In the subgroup analyses by ethnicity, study sample size, endometriosis-associated infertility, and stage of endometriosis, a significantly increased risk was observed among mixed populations (dominant model, OR = 2.03, 95% CI = 1.56–2.64) and among cases with endometriosis-associated infertility (dominant model, OR = 1.83, 95% CI = 1.26–2.67). Regarding the rs1256049 polymorphism, no obvious associations were found for all genetic models in the overall population. Subgroup analyses by ethnicity and study sample size revealed that only one study of a mixed population with small sample size showed an increased risk of endometriosis. No publication bias was found in the present study.

Conclusions: The results of this meta-analysis suggest that the ER-β rs4986938 and rs1256049 polymorphisms may not be associated with endometriosis risk, while the observed increased risk of endometriosis-associated infertility may be due to bias by the inclusion of small-scale studies.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_184

Keywords: Endometriosis, Estrogen receptor-beta, Polymorphism, Meta-analysis

Background

Endometriosis is a steroid-dependent condition defined by the presence of endometrial tissue outside of the uterine cavity resulting in diverse clinical manifestations, such as infertility, pelvic pain, and dysmenorrhea [1]. Endometriosis affects 3%–10% of reproductive-aged women and 20%–50% of women with infertility [2]. Susceptibility to endometriosis is dependent on a complex interaction of genetic, immunological, and hormonal factors [3-5]; however, the exact etiology and pathogenesis of the disease remain unclear.

Estrogen has been shown to play a critical role in the growth of endometriotic tissues [6]. By binding to the estrogen receptor (ER), estrogen triggers a broad array of tissue and organ-specific physiological responses. There are two isoforms of ERs, ER-α and ER-β, which exhibit distinct distribution patterns among differentiated cells...
and tissues [7]. With the binding of ligands, ERs are translocated to the nucleus to activate gene transcription. Previous studies have demonstrated that allelic variants of genes encoding for ER may be responsible for their action as modulators of the estrogenic response, and the polymorphisms of these genes have been postulated as candidate risk markers for a number of estrogen-dependent disorders, including endometriosis [8,9]. The ER-β gene is located on the long arm of chromosome 14 at locus 2 among subloci 23 and 24 (14q22–24). Two single nucleotide polymorphisms (SNPs) in the ER-β gene, rs4986938 and rs1256049, have been most frequently studied. The former SNP located in exon 8 gives rise to a G-A exchange at nucleotide 1730 and introduces a recognition site for AluI, whereas the latter results in a G-A exchange at nucleotide 1082 in exon 5 and creates a recognition site for Rsal. In recent years, many meta-analyses have reported associations of these two SNPs in the ER-β gene with several diseases, including prostate cancer [10], male infertility [11], Parkinson's disease [12], osteoarthritis [13], and breast cancer [14].

To date, a great number of case–control studies have been conducted to investigate the associations between the ER-β rs4986938 and rs1256049 polymorphisms and endometriosis risk in humans. However, the results of published studies are inconclusive and even controversial [15–23], and the associations between ER-β gene polymorphisms and the risk of endometriosis-associated infertility remain unclear, which could be due to differences in the studied populations and insufficient statistical power. Thus, we conducted this meta-analysis to explore the exact associations between the rs4986938 and rs1256049 polymorphisms of the ER-β gene and risk of endometriosis.

Methods

Publication search

A systematic literature search of the PubMed, ISI Web of Science, and several Chinese language databases (Biomedical Literature Database, Chinese National Knowledge Infrastructure, and Chinese Wanfang Data) was carried out to identify studies involving the associations between the ER-β rs4986938 and rs1256049 polymorphisms and endometriosis risk. No language restrictions were applied. To search and include as many related studies as possible, we used different combinations of the following key words: (estrogen receptor beta or estrogen receptor β or ER-β) and (polymorphism or variant or mutation) and endometriosis. All references of the retrieved studies were also reviewed to identify other relevant publications. Review articles were also searched to find additional eligible studies. If more than one article was published using the same study data, only the study with largest sample size was included. The literature search was updated on June 20, 2014.

Inclusion and exclusion criteria

Studies fulfilling the following selection criteria were included in this meta-analysis: (1) case–control design; (2) evaluation of the correlation of the two SNPs (rs4986938 and rs1256049) of the ER-β gene with endometriosis risk; (3) provision of sufficient data to calculate the odds ratio (OR) and its corresponding 95% confidence interval (CI). Studies were excluded if one of the following criteria existed: (1) no relevance to the rs4986938 and rs1256049 polymorphisms, ER-β, and endometriosis; (2) non-clinical; and (3) review articles or commentaries. When several studies with overlapping data were eligible, those with the smaller sample size or less reliability were excluded. Furthermore, studies without detailed information were excluded after efforts to extract data from the original paper or contact the corresponding authors failed.

Data extraction

Two authors (Renyong Guo and Nengneng Zheng) independently assessed the quality of each study. Any disagreement was resolved by consensus. The following information was extracted: name of first author, year of publication, country of origin, ethnicity of the study population, number of cases and controls, mean age of subjects and controls, number of infertility cases, genotype distributions in cases and controls, and probability (p) value for the test of Hardy–Weinberg equilibrium (HWE) in controls. Discrepancies occurring during the process of study selection and data extraction were resolved by discussion with a third reviewer (Limin Feng) to arrive at a consensus on each item.

Statistical analysis

The strength of an association between the two ER-β gene polymorphisms and endometriosis risk was measured by OR with its corresponding 95% CI. The pooled ORs were calculated for the following four genetic models: (1) allelic model: allele A vs. G, where A = variant allele and G = wild allele, (2) homozygote comparison: AA vs. GG, (3) heterozygote comparison: GA vs. GG, (4) dominant model: AA + GA vs. GG, and (5) recessive model: AA vs. GA + GG. The statistical significance of the pooled OR was assessed with the Z test and a p value < 0.05 was considered statistically significant. A chi-square-based Q test was conducted to measure the heterogeneity between eligible studies and the existence of heterogeneity was considered significant at p < 0.10 [24]. When between-study heterogeneity was absent, a fixed effect model (Mantel–Haenszel method) was used to pool the data from different studies [25]; otherwise, a random-effects model using the DerSimonian–Laird method was applied [26]. Subgroup analyses were also conducted based on ethnicity, study sample size, endometriosis-associated infertility, and stage of endometriosis. Sensitivity analyses were performed to identify the
effect of each individual study on pooled results and to test the reliability of results by deleting a single study each time [27]. Begg’s test and Egger’s test were performed to determine the presence of publication bias with $p < 0.05$ considered statistically significant [28,29]. Data analysis was performed using STATA statistical software (version 12.0; Stata Corporation, College Station, TX, USA).

Results
Characteristics of eligible studies
The literature search identified a total of 90 potentially relevant papers. After removing 29 duplications and reading the titles and abstracts, a further 45 articles were excluded. A total of 16 remaining articles were then retrieved for further assessment of eligibility. Among these studies, seven were excluded because they were (1) reviews or meta-analysis [30-33], (2) not regarding gene polymorphisms [34], (3) an infertile control study [35], or (4) lacked useful data [36]. Finally, a total of nine eligible articles were included in this meta-analysis. The detailed screening process is shown in Figure 1, which was modified according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement [37]. Among these nine eligible studies, eight and four studies were pooled for analysis of the rs4986938 and rs1256049 polymorphisms, respectively. Regarding ethnicity, five studies assessed Asians [15-17,20,22] and four studies evaluated mixed ethnicities [18,19,21,23]. All of the included studies employed a case–control design and the genotype distributions among the controls of all studies were consistent with the HWE. The characteristics of the included studies are listed in Table 1.

Quantitative synthesis

ER-β rs4986938 polymorphism
A total of seven studies with 1100 cases and 1485 controls were included to examine the association between the ER-β rs4986938 polymorphism and endometriosis risk. The overall results suggested no statistically significant association of this polymorphism with endometriosis susceptibility (dominant model, $OR = 1.21$, 95% CI = 0.83–1.77; recessive model, $OR = 0.86$, 95% CI = 0.41–1.77; AA vs. GG, $OR = 0.95$, 95% CI = 0.46–1.97; GA vs. GG, $OR = 1.24$, 95% CI = 0.80–1.91; A vs. G, $OR = 1.16$, 95% CI = 0.82–1.64; Table 2). In regard to subgroup analysis by study sample size ($\leq 300$ and $> 300$ subjects), the non-associations in the above-mentioned genetic models remained. However, further subgroup analyses based on ethnicities demonstrated that the...
### Table 1 Characteristics of the studies included in the meta-analysis of ER-β gene polymorphisms and endometriosis

| Study | Year | Country | Ethnicity | Age, years, mean ± SD | Sample size | No. of infertility cases | Source of controls | Cases (Genotype) | Controls Genotype | $P_{\text{HWE}}$ |
|-------|------|---------|-----------|-----------------------|-------------|--------------------------|-------------------|----------------|------------------|-------|
|       |      |         |           | Cases | Controls | Cases | Controls |                      | G/G | G/A | A/A | G/G | G/A | A/A | |
| rs4986938 |      |         |           |       |         |       |         |                      |     |     |     |     |     |     | |
| Wang [16] | 2004 | Japan   | Asia      | NA   | NA      | 127   | 180     | NA                | HB  | 104 | 22 | 1  | 130 | 49 | 1 | 0.26 |
| Huang [21] | 2005 | China   | Asia      | 35.0 ± 10.0 | 34.0 ± 10.0 | 110   | 115     | NA                | PB  | 78  | 27 | 5  | 82  | 29 | 4 | 0.48 |
| Lee [18] | 2007 | Korea   | Asia      | 33.8 ± 6.7 | 41.6 ± 10.7 | 239   | 287     | NA                | HB  | 179 | 60 | 0  | 208 | 75 | 4 | 0.34 |
| Bianco [19] | 2009 | Brazil  | Mixed     | 34.1 ± 4.2 | 39.8 ± 4.5 | 108   | 210     | 108               | HB  | 55  | 51 | 2  | 156 | 51 | 3 | 0.61 |
| Zulli [20] | 2010 | Brazil  | Mixed     | 33.7 ± 4.0 | 39.8 ± 4.5 | 136   | 209     | 136               | HB  | 82  | 52 | 2  | 162 | 44 | 3 | 0.99 |
| Gu [17] | 2012 | China   | Asia      | 45.0 ± 6.0 | 40.0 ± 19.0 | 58    | 107     | NA                | HB  | 47  | 11 | 0  | 80  | 27 | 0 | 0.14 |
| Christofolini [22] | 2011 | Brazil  | Mixed     | 35.2 ± 3.9 | 34.4 ± 4.7 | 201   | 206     | 201               | HB  | 123 | 76 | 2  | 145 | 58 | 3 | 0.30 |
| Wu [23] | 2013 | China   | Asia      | 30.9 ± 6.3 | 29.1 ± 4.3 | 121   | 171     | 121               | NA  | 97  | 24 | 1  | 140 | 31 | 1 | >0.05 |
| rs1256049 |      |         |           |       |         |       |         |                      |     |     |     |     |     |     | |
| Wang [16] | 2004 | Japan   | Asia      | NA   | NA      | 131   | 182     | NA                | HB  | 71  | 56 | 4  | 98  | 73 | 11 | 0.59 |
| Huang [21] | 2005 | China   | Asia      | 35.0 ± 10.0 | 34.0 ± 10.0 | 110   | 115     | NA                | PB  | 17  | 55 | 38 | 30  | 61 | 24 | 0.49 |
| Silva [24] | 2011 | Brazil  | Mixed     | 32.5c | 37.4c | 54    | 46      | 27                | NA  | 22  | 32 | 0  | 43  | 3  | 0 | 0.82 |
| Gu [17] | 2012 | China   | Asia      | 45.0 ± 6.0 | 40.0 ± 19.0 | 58    | 107     | NA                | HB  | 27  | 19 | 12 | 50  | 45 | 12 | 0.70 |

HB, hospital-based; PB, population-based; NA, not available; No., number.

*GA + AA; b$p$ value for Hardy–Weinberg equilibrium in controls; cMean age, years.
| Comparison | No. of studies | A vs. G\(^b\) | AA vs. GG\(^{a,b}\) | GA vs. GG\(^b\) | AA + GA vs. GG | AA vs. GA + GG\(^{a,b}\) |
|------------|----------------|---------------|---------------------|-----------------|----------------|-------------------------|
|            |                | OR (95% CI)   | \(P\_H\)           | OR (95% CI)     | \(P\_H\)       | OR (95% CI)             | \(P\_H\)       | OR (95% CI)             | \(P\_H\)       |
| Overall    | 8              | 1.16 (0.82-1.64\(^{a}\)) | <0.001       | 0.95 (0.46-1.97\(^{f}\)) | 0.735       | 1.24 (0.80-1.91\(^{a}\)) | <0.001       | 1.21 (0.83-1.77\(^{a}\)) | <0.001       | 0.86 (0.41-1.77\(^{f}\)) | 0.790       |
|            |                |               |                     |                 |               |                         |             |                         |             |                         |             |
| ethnicity  |                |               |                     |                 |               |                         |             |                         |             |                         |             |
| Asia       | 5              | 0.82 (0.65-1.04\(^{f}\)) | 0.552          | 0.75 (0.27-2.07\(^{f}\)) | 0.335       | 0.81 (0.62-1.05\(^{f}\)) | 0.456       | 0.85 (0.67-1.08\(^{f}\)) | 0.496       | 0.91 (0.26-3.13\(^{f}\)) | 0.331       |
| Mixed      | 3              | 1.72 (1.37-2.17\(^{f}\)) | 0.204          | 1.23 (0.43-3.49\(^{f}\)) | 0.795       | 2.08 (1.59-2.71\(^{f}\)) | 0.159       | 2.03 (1.56-2.64\(^{f}\)) | 0.148       | 0.97 (0.34-2.74\(^{f}\)) | 0.880       |
| Sample size|                |               |                     |                 |               |                         |             |                         |             |                         |             |
| >300       | 5              | 1.26 (0.82-1.93\(^{a}\)) | <0.001       | 0.83 (0.34-1.99\(^{f}\)) | 0.611       | 1.41 (0.82-2.40\(^{a}\)) | <0.001       | 1.38 (0.81-2.34\(^{a}\)) | <0.001       | 0.71 (0.30-1.73\(^{f}\)) | 0.717       |
| ≤300       | 3              | 0.94 (0.62-1.41\(^{f}\)) | 0.412         | 1.31 (0.34-5.07\(^{f}\)) | -           | 0.86 (0.53-1.39\(^{f}\)) | 0.498       | 0.97 (0.67-1.39\(^{f}\)) | 0.624       | 1.32 (0.35-5.06\(^{f}\)) | -           |

OR, odds ratio; CI, confidence interval; No., number; \(P\_H\), \(p\) value of Q-test for heterogeneity test; R, random-effect model; F, fixed-effect model.

\(^{a}\)The study by Gu et al. was not included since they presented 0 frequency of AA genotype in cases and controls.

\(^{b}\)The study by Wu et al. was not included since they just presented the data on GG and GA + AA genotypes in cases and controls.

\(^{c}\)Statistically significant results (in bold).
ER-β rs4986938 polymorphism was significantly associated with an increased risk of endometriosis in mixed populations (dominant model, OR = 2.03, 95% CI = 1.56–2.64; GA vs. GG, OR = 2.08, 95% CI = 1.59–2.71; A vs. G, OR = 1.72, 95% CI = 1.37–2.17; Table 2, Figure 2). Additionally, four studies (566 cases and 796 controls) [18,19,21,22] provided data between the rs4986938 polymorphism and risk of endometriosis-associated infertility. The subsequent subgroup analysis showed that the ER-β rs4986938 polymorphism was also significantly associated with an increased risk of endometriosis-associated infertility (dominant model, OR = 1.83, 95% CI = 1.26–2.67; recessive model, OR = 0.96, 95% CI = 0.34–2.72; AA vs. GG, OR = 1.23, 95% CI = 0.43–3.49; GA vs. GG, OR = 2.08, 95% CI = 1.59–2.71; A vs. G, OR = 1.72, 95% CI = 1.37–2.17; Figure 3). Data on genotype distributions of the rs4986938 polymorphism in patients with stage I–II and III–IV endometriosis were also available in three studies [17,18,21]. The results showed no significant association of the rs4986938 polymorphism with stage of endometriosis (stage III–IV vs. stage I–II) (dominant model, OR = 1.01, 95% CI = 0.69–1.49; recessive model, OR = 0.34, 95% CI = 0.05–2.29; AA vs. GG, OR = 0.33, 95% CI = 0.05–2.29; GA vs. GG, OR = 1.05, 95% CI = 0.71–1.54; A vs. G, OR = 0.98, 95% CI = 0.70–1.36; Figure 4).

ER-β rs1256049 polymorphism
A total of 353 cases and 450 controls were identified to assess the association between the rs1256049 polymorphism and endometriosis risk. The overall results suggested no statistically significant association of this polymorphism with endometriosis susceptibility (dominant model, OR = 2.11, 95% CI = 0.85–5.26; recessive model, OR = 1.43, 95% CI = 0.66–3.08; AA vs. GG, OR = 1.50, 95% CI = 0.59–3.79; GA vs. GG, OR = 1.95, 95% CI = 0.75–5.09; A vs. G, OR = 1.71, 95% CI = 0.92–3.16; Table 3). Further subgroup analysis suggested that the effect size was only significant among mixed populations (dominant model, OR = 20.85, 95% CI = 5.74–75.75; GA vs. GG, OR = 20.85, 95% CI = 5.74–75.75; A vs. G, OR = 12.49, 95% CI = 3.68–42.41), but not among Asian populations under all genetic models (Figure 5). Subgroup analysis by study sample size (≤200 and > 200 subjects) revealed no obvious associations.

**Heterogeneity test and sensitivity analysis**
During the meta-analysis, significance of between-study heterogeneity was observed (Tables 2 and 3). To explore the source of heterogeneity, subgroup analyses by ethnicity and sample size were conducted. Furthermore, sensitivity analyses were performed to explore the influence of each individual study on the overall results by deleting a single study each time from the pooled analysis. This procedure confirmed that our results of the ER-β rs4986938 and rs1256049 polymorphisms and endometriosis susceptibility were both reliable and robust (Figure 6).

![Figure 2](http://www.diagnosticpathology.org/content/9/1/184)
Potential publication bias

To assess possible publication bias in the currently available literature, Begg’s test and Egger’s test were performed, which showed no publication bias for studies published on the rs4986938 and rs1256049 polymorphisms (all \( p > 0.05 \), Table 4).

Discussion

ERs are nuclear receptors that contain an estrogen-binding domain and a DNA-binding domain. Studies on tissue distribution and expression patterns indicate that ER-\( \alpha \) has a broad expression pattern, whereas ER-\( \beta \) has a more focused pattern with high levels in the ovary, prostate, epididymis, lung, and hypothalamus [38]. Fazleabas et al. examined expression levels of ER-\( \alpha \), ER-\( \beta \), and progesterone receptors in baboons and found that ER-\( \beta \) was the dominant steroid receptor present in endometriotic explants, regardless of the cycle phase [39]. Two meta-analyses demonstrated that the PvuII (T/C) and XbaI (A/G) polymorphisms of the ER-\( \alpha \) gene may not be associated with endometriosis risk [30,40]. Over the last 10 years, a great number of studies have investigated the association between ER-\( \beta \) gene polymorphisms and endometriosis risk, with most focused on the ER-\( \beta \) rs4986938 and rs1256049 polymorphisms. However, some of the results were conflicting, even in the same population, and thus a systematic review and meta-analysis of associations between ER-\( \beta \) gene polymorphisms and endometriosis risk will be of great value.

To the best of our knowledge, this is the first meta-analysis to assess the relationship between the two ER-\( \beta \) gene polymorphisms and endometriosis risk across different ethnic populations and sample sizes. Even though the association of endometriosis risk and genetic
| Comparison | No. of studies | A vs. G | AA vs. GG | GA vs. GG | AA + GA vs. GG | AA vs. GA + GG |
|------------|----------------|---------|-----------|-----------|----------------|----------------|
|            |                | OR (95% CI) | P \(H\) | OR (95% CI) | P \(H\) | OR (95% CI) | P \(H\) | OR (95% CI) | P \(H\) | OR (95% CI) | P \(H\) |
| Overall    | 4              | 1.71 (0.92-3.16) | <0.001 | 1.50 (0.59-3.79) | 0.059 | 1.95 (0.75-5.09) | <0.001 | 2.11 (0.85-5.26) | <0.001 | 1.43 (0.66-3.08) | 0.089 |
| Ethnicity  |                |         |           |           |                 |                 |         |           |           |                 |                 |
| Asia       | 3              | 1.23 (0.86-1.75) | 0.094 | 1.50 (0.59-3.79) | 0.059 | 1.09 (0.78-1.53) | 0.371 | 1.17 (0.85-1.61) | 0.229 | 1.43 (0.66-3.08) | 0.089 |
| Mixed      | 1              | **12.49 (3.68-42.41)** | - | - | - | **20.85 (5.74-75.75)** | - | **20.85 (5.74-75.75)** | - | - | - |
| Sample size|                |         |           |           |                 |                 |         |           |           |                 |                 |
| >200       | 2              | 1.22 (0.69-2.16) | 0.03 | 1.26 (0.23-6.76) | 0.018 | 1.20 (0.82-1.76) | 0.341 | 1.22 (0.85-1.77) | 0.101 | 1.08 (0.28-4.27) | 0.035 |
| ≦200       | 2              | 3.68 (0.36-37.65) | <0.001 | 1.85 (0.73-4.68) | - | 3.86 (0.15-102.43) | <0.001 | 4.35 (0.21-89.43) | <0.001 | 2.07 (0.86-4.95) | - |

**Table 3** Summary ORs and 95% CIs of the association between ER-β rs1256049 polymorphism and endometriosis

OR, odds ratio; CI, confidence interval; No., number; P \(H\), P value of Q-test for heterogeneity test; R, random-effect model; F, fixed-effect model.

*The study by Silva et al. was not included since they presented 0 frequency of AA genotype in cases and controls.

*Statistically significant results (in bold).
polymorphisms involving biosynthesis of sex steroids and their receptors was assessed in a previous meta-analysis [30], the results only presented an allelic model of the ER-β rs4986938 and rs1256049 polymorphisms from five relevant studies. Our results suggested that there was no significant association between the rs4986938 and rs1256049 polymorphisms in the ER-β gene and endometriosis risk in the overall population, which was consistent with the results of a previous meta-analysis [30]. For the rs4986938 polymorphism, there was no statistically significant association among study sample size, stage of endometriosis, and Asian population in further subgroup analyses. However, obvious associations were found among mixed populations for rs4986938 polymorphisms under the allelic, heterogeneous co-dominant and dominant models. Different ethnic groups have unique genetic backgrounds and may produce variations of genetic factors involved in the pathogenesis of endometriosis [18]. The results of subgroup analyses indicated that ethnicity might be the source of heterogeneity across studies. However, a characteristic of three studies were mixed populations that included infertile Brazilian women with endometriosis. Therefore, the rs4986938 polymorphisms may be not associated with endometriosis risk, while the observed increase in the risk of endometriosis in mixed populations may be due to the complication of infertility. Regarding the rs1256049 polymorphism, no obvious associations were also found in all genetic models.
of the overall population and in subgroup analyses by study sample size. In the subgroup analyses based on ethnicity, however, only one study of a mixed population found an increased risk of endometriosis under allelic, heterogeneous co-dominant and dominant models of the rs1256049 polymorphism. Inherent genetic differences and variances in sample size between Asian and mixed population studies might be a potential explanation for the observed heterogeneity.

It should be noted that not all studies addressed the correlation of ER-β gene polymorphisms with the pathogenesis or risk of endometriosis-associated infertility. Regarding the rs4986938 polymorphism, only four studies evaluated the effect of interactions, with three studies [18,19,21] providing complete data on genotype distribution in cases and controls and one [22] just presenting data on GG and GA + AA genotypes in cases and controls. Regarding the rs1256049 polymorphism, since only one study [23] for endometriosis-associated infertility was investigated and the sample size was small, subgroup analysis of endometriosis-associated infertility was not performed. Nonetheless, the results demonstrated a significant association between the rs4986938 polymorphism and risk of endometriosis-associated infertility. Human fertility is a complex feature influenced by interactions between genetic and environmental factors. Saunders et al. reported that the ER-β gene plays an important role in the regulation of fertility in both males and females [41]. Another study performed with female ER-β knockout mice also demonstrated that ER-β proteins, which can be detected in multiple cell types throughout the female reproductive system, are essential for normal ovulation efficiency [42-44]. However, the functional significance of the rs4986938 polymorphism remains to be clarified. No amino acid changes in the ER-β protein occur under the conditions of ER-β gene rs4986938 mutations, whereas these polymorphisms are possibly in linkage disequilibrium with variations of other regulatory sequences that may affect gene expression or function [45]. Furthermore, structural folds of mRNA might change, accounting for the existence of SNPs, and could result in different biological functions that interact with other cellular components [46]. Endometriosis is noted in up to 20%–50% of infertile women, but the reason why women with endometriosis have impaired fertility remains uncertain [2]. The above reason might partly explain the potential association of polymorphic sites in the ER-β gene with endometriosis and endometriosis-associated infertility among different populations. However, it would be of great interest to characterize the actual relationship between ER-β gene polymorphisms and endometriosis and/or infertility in a large-scale study.

Several limitations to this study should be addressed. First, the results of our meta-analysis should be interpreted with caution because the sample size was relatively small for the subgroup analysis according to endometriosis-associated infertility and stage of endometriosis. Second, our meta-analyses were based on unadjusted estimates and therefore potential covariates, which might influence the effect estimates, were not controlled. Third, there were relatively few studies on the association of the rs1256049 polymorphism and endometriosis. Therefore, subgroup analysis according to endometriosis-associated infertility and stage of endometriosis was not performed. Hence, further studies with larger sample sizes to provide more detailed information are needed.

Conclusions

In conclusion, the results of this study suggest that the ER-β rs4986938 and rs1256049 polymorphisms may be not associated with endometriosis risk. However, ER-β rs4986938 is likely associated with endometriosis-associated infertility, and it might also act as a modifier of the relationship between risk of endometriosis-associated infertility and some environmental factors. To date, there is insufficient evidence implicating the ER-β rs4986938 polymorphism in the etiology of endometriosis-associated infertility for population testing. The observed increase in risk of endometriosis-associated infertility may be due to bias because of the inclusion of small-scale studies. It is critical that larger and well-designed multicenter studies should be performed to re-evaluate potential associations.

Competing interests
The authors declare that they have no competing interests.
Authors' contributions
All authors participated in the study design, data analysis, interpretation of the results, and review of the manuscript. NNZ and YZ conducted the experiments; RYG, NNZ, and SPD analyzed the data; and RYG and LMF wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was financially supported by a grant from the Department of Education Foundation of Zhejiang Province, China (grant No: Y201330146).

Author details
1Department of Laboratory Medicine, First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79 Qinchun Road, Hangzhou, Zhejiang 310003, China. 2Department of Gynecology and Obstetrics, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China. 3State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.

Received: 25 July 2014 Accepted: 7 September 2014

References
1. Missmer SA, Caan BW: The epidemiology of endometriosis. Obstet Gynecol Clin North Am 2003, 30:1–19.
2. Gao X, Outley J, Bottomen M, Spalding J, Simon JA, Pashos CL: Economic burden of endometriosis. Fertil Steril 2006, 86:1561–1572.
3. Vignani P, Soragni E, Vignali M, Busacca M, Biasio AM: Genetics of endometriosis: current status and prospects. Front Biosci 2007, 12:3247–3255.
4. Simpson JL, Bischoff FZ: Heritability and molecular genetic studies of endometriosis. Ann NY Acad Sci 2002, 955:239–251.
5. Gortz EJ, Steedhan SP: Mediators of communication and adaptation in the neuroendocrine and immune systems. FASEB J 1992, 6:2546–2552.
6. Georgiou I, Syrrou M, Bouba I, Dalkalitsis N, Paschopoulos M, Navrozoglou I, Lolis D: Association of estrogen receptor gene polymorphisms with endometriosis. Fertil Steril 1999, 72:164–166.
7. Sniege N, Liu B, Yin G, Gong Y, Arun BK: Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Mod Pathol 2006, 19:622–629.
8. Hsieh YY, Wang YK, Chang CC, Lin CS: Estrogen receptor alpha 351 XbalG and –397 PvuII*C-related genotypes and alleles are associated with higher susceptibilities of endometriosis and leiomyoma. Mol Hum Reprod 2007, 13:117–122.
9. Wieser F, Schneebelter C, Tong D, Tempfer C, Huber JC, Wenzl R: Common genetic variation in the Estrogen Receptor Beta gene is related to infertility and infertility-associated endometriosis. Arq Bras Endocrinol Metabol 2010, 54:567–571.
10. Ge YZ, Xu LW, Jie SY, Huang JX, Ge W: Relationship between DRA and ERβ gene polymorphisms and endometriosis susceptibility. J Diagn Concepts Pract 2012, 11:401–406.
11. Lee GH, Kim SH, Choi YM, Suh CS, Kim JG, Moon SY: Estrogen receptor beta gene +1730 G > A polymorphism in women with endometriosis. Fertil Steril 2007, 88:785–789.
12. Bianco B, Christofolini DM, Mafra FA, Brandes A, Zulli K, Barbosa CP: +1730 G > A polymorphism of the estrogen receptor beta gene (ERBeta) may be an important genetic factor predisposing to endometriosis. Acta Obstet Gynecol Scand 2009, 88:1397–1401.
13. Zulli K, Bianco B, Mafra FA, Teles JS, Christofolini DM, Barbosa CP: Polymorphism of the estrogen receptor β gene is related to infertility and infertility-associated endometriosis. Acta Obstet Gynecol Scand 2009, 88:1397–1401.
14. Gu YC, Cai Q, Jiang ZY, Zhu JS, Zhu LR: Relationship between DRA and ERβ gene polymorphisms and endometriosis susceptibility. J Diagn Concepts Pract 2012, 11:401–406.
15. Lee GH, Kim SH, Choi YM, Suh CS, Kim JG, Moon SY: Estrogen receptor beta gene +1730 G > A polymorphism in women with endometriosis. Fertil Steril 2007, 88:785–789.
16. Bianco B, Christofolini DM, Mafra FA, Brandes A, Zulli K, Barbosa CP: +1730 G > A polymorphism of the estrogen receptor beta gene (ERBeta) may be an important genetic factor predisposing to endometriosis. Acta Obstet Gynecol Scand 2009, 88:1397–1401.
17. Zulli K, Bianco B, Mafra FA, Teles JS, Christofolini DM, Barbosa CP: Polymorphism of the estrogen receptor β gene is related to infertility and infertility-associated endometriosis. Arq Bras Endocrinol Metabol 2010, 54:567–571.
18. Huang HL, Wei YS, Jie SY, Huang JX, Fang YX: A case-control study on the association of Estrogen receptor-beta polymorphism and endometriosis risk. Chin J Obstet Gynecol 2005, 40:644–645.
19. Christofolini DM, Vlaminck FL, Mafra FA, Andrade GM, Bianco B, Barbosa CP: Combination of polymorphisms in luteinizing hormone β, estrogen receptor β and progesterone receptor and susceptibility to infertility and endometriosis. Eur J Obstet Gynecol Reprod Biol 2011, 158:260–264.
20. Wu CH, Yang JG, Hsu CC, Kuo PL: Screening of a panel of steroid-related genes showed polymorphisms of aromatase gene confer susceptibility to advanced stage endometriosis in the Taiwanese Han population. Taiwan J Obstet Gynecol 2013, 52:85–92.
21. Silva RC, Costa IR, Bordin BM, Silva CT, Souza SR, Júnior FA, Mafra FA, Barbosa CP: The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk. J Assist Reprod Genet 2014, 31:501–507.
22. Wu CH, Yang JG, Chang YJ, Hsu CC, Kuo PL: The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk. J Assist Reprod Genet 2014, 31:501–507.
23. Silva RC, Costa IR, Bordin BM, Silva CT, Souza SR, Júnior FA, Mafra FA, Barbosa CP: The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk. J Assist Reprod Genet 2014, 31:501–507.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557–560.
25. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719–748.
26. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177–188.
27. Thakkinstian A, McElruff P, D'Este C, Duffy D, Attia J: A method for meta-analysis of molecular association studies. Stat Med 2005, 24:1291–1306.
28. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088–1101.
29. Egger M, Davey Smith G, Schneider M, Minder C: Bias in metaanalysis detected by a simple, graphical test. BMJ 1997, 315:629–634.
30. Hu X, Zhou Y, Feng Q, Wang R, Su L, Long J, Wei B: Association of endometriosis risk and genetic polymorphisms involving biosynthesis of sex steroids and their receptors: an updating meta-analysis. Eur J Obstet Gynecol Reprod Biol 2012, 164:1–9.
31. Kitawaki J, Kado N, Ishihara H, Koshida H, Kitaoka Y, Honjo H: Endometriosis: the pathophysiology as an estrogen-dependent disease. Steroid Biochem Mol Biol 2002, 83:149–155.
32. Burns KA, Korach KS: Endometriosis and human disease: an update. Arch Toxicol 2012, 86:1491–1504.
33. Ness RB: Endometriosis and ovarian cancer: Thoughts on shared pathophysiology. J Am Obstet Gynecol 2003, 189:280–294.
34. Juhász-Böss I, Fischer C, Latrich C, Székelyczak M, Makk E, Ottmann O, Treeck O: Endometrial expression of estrogen receptor beta 1 and its splice variants in patients with and without endometriosis. Arch Gynecol Obstet 2011, 284:885–891.
35. Tsuchiya M, Miura T, Hanaoka T, Iwasači M, Sasaki H, Tanaka T, Nakao K, Katoh T, Ikonomou T, Kabuto M, Tsuigane S: Effect of soy isoflavones on endometriosis: interaction with estrogen receptor 2 gene polymorphism. Gynecol Endocrinol 2007, 18:402–408.
36. Luisi S, Galleri L, Marini F, Ambrosini G, Brandi ML, Petraglia F: Estrogen receptor gene polymorphisms are associated with recurrence of endometriosis. Fertil Steril 2006, 85:764–766.
37. Moret D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plots Med Res 2009, 408:e1000097.
38. Coude JE, Lindsey J, Gravenda K, Gustafsson JA, Korach KS: Tissue distribution and quantitative analysis of estrogen receptoralpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 1997, 138:4613–4621.
39. Fazleabas AT, Brudney A, Gutures B, Chai D, Bulun S: A modified baboon model for endometriosis. Ann NY Acad Sci 2002, 955:308–317.
40. Li Y, Liu F, Tan SQ, Wang Y, Li SW: Estrogen receptor-alpha gene PvuII (T C) and XbaI (A G) polymorphisms and endometriosis risk: a meta-analysis. Gene 2012, 508:41–48.

41. Saunders PT: Does estrogen receptor beta play a significant role in human reproduction? Trends Endocrinol Metab 2005, 16:222–227.

42. Krieger JH, Hodge JF, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O: Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 1998, 95:15677–15682.

43. Scobie GA, Macpherson S, Millar MR, Groome NP, Romana PG, Saunders PT: Human oestrogen receptors: differential expression of ER alpha and beta and the identification of ER beta variants. Steroids 2002, 67:985–992.

44. Critchley HO, Henderson TA, Kelly RW, Scobie GS, Evans LR, Groome NP, Saunders PT: Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbeta2cx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle. J Clin Endocrinol Metab 2002, 87:5265–5273.

45. Yaich L, Dupont WD, Cavener DR, Parl FF: Analysis of the PvuII restriction fragment length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 1992, 52:77–83.

46. Shen LX1, Basilion JP, Stanton VP Jr: Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci U S A 1999, 96:7871–7876.

Cite this article as: Guo et al.: Associations between estrogen receptor-beta polymorphisms and endometriosis risk: a meta-analysis. Diagnostic Pathology 2014 9:184.